Cargando…

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

Conventional regimens have limited impact against non-small cell lung cancer (NSCLC). Current research is focusing on multiple pathways as potential targets, and this study investigated molecular mechanisms underlying the combination of the PKCβ inhibitor enzastaurin with the multitargeted antifolat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tekle, C, Giovannetti, E, Sigmond, J, Graff, J R, Smid, K, Peters, G J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528136/ https://www.ncbi.nlm.nih.gov/pubmed/18728666 http://dx.doi.org/10.1038/sj.bjc.6604566

Ejemplares similares

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules
por: Körner, A, et al.
Publicado: (2010)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats
por: Willeman, Mari N., et al.
Publicado: (2018)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
por: Benhadji, K A, et al.
Publicado: (2008)

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005)

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
por: Taylor-Harding, B, et al.
Publicado: (2012)

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
por: Eisner, Joel R., et al.
Publicado: (2023)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
por: Kususda, Y, et al.
Publicado: (2012)

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
por: Wang, L-H, et al.
Publicado: (2014)

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells
por: Sudhagar, S, et al.
Publicado: (2011)

The α(2)β(1) integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines
por: Grzesiak, J J, et al.
Publicado: (2006)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death
por: Hotfilder, M, et al.
Publicado: (2005)

The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

ATP7A is a novel target of retinoic acid receptor β(2) in neuroblastoma cells
por: Bohlken, A, et al.
Publicado: (2009)

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours
por: Khandelwal, A, et al.
Publicado: (2008)

Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells
por: Stein, U, et al.
Publicado: (2012)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer
por: Xu, S, et al.
Publicado: (2015)

Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer
por: Christoph, D C, et al.
Publicado: (2012)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB
por: Jacobs, H, et al.
Publicado: (2011)

Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway
por: Ghebeh, H, et al.
Publicado: (2014)

[(18)F]FDG and [(18)F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study
por: Direcks, W G E, et al.
Publicado: (2008)

Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion
por: Siret, Carole, et al.
Publicado: (2015)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_317lob9bf9ff9m7c9emqg03ie6